Category - Developments

Profound Medical (TSXV:PRN) has entered into an agreement with a syndicate of underwriters, led by Canaccord Genuity, to sell on a bought deal basis a total of 30 million units at a price of $1 each for gross proceeds...

VolitionRx (NYSE American:VNRX) announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark, with...

Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study included 59 urine samples (28...

Closely-held RPS Diagnostics and Atomo Diagnostics of Australia have entered into a commercial and development partnership to create next generation FebriDx tests that are anticipated to transform the diagnosis of...

Closely-held Scientus Pharma has completed a private placement of common shares at a price of $4 each for gross proceeds of approximately $15.8-million. Net proceeds will be used for working capital and general...

Evotec AG (Frankfurt Stock Exchange:EVT) and MaRS Innovation announced the first project to be developed under their LAB150 partnership would target an unmet medical need in skin inflammatory conditions. The project...

DarioHealth (NASDAQ:DRIO) has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of the art...

DarioHealth (NASDAQ:DRIO) has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes that will use DarioHealth to run and track blood glucose...

Lipocine (NASDAQ:LPCN) announced receipt of $10-million in January by means of a loan and security agreement with Silicon Valley Bank. “This debt facility strengthens our balance sheet and provides increased...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients...